252 related articles for article (PubMed ID: 33446083)
1. Tenecteplase in wake-up ischemic stroke trial: Protocol for a randomized-controlled trial.
Roaldsen MB; Lindekleiv H; Eltoft A; Jusufovic M; Søyland MH; Petersson J; Indredavik B; Tveiten A; Putaala J; Christensen H; Kõrv J; Jatužis D; Engelter ST; Marco De Marchis G; Wilsgaard T; Werring DJ; Robinson T; Mathiesen EB; Berge E
Int J Stroke; 2021 Oct; 16(8):990-994. PubMed ID: 33446083
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of tenecteplase in patients with wake-up stroke assessed by non-contrast CT (TWIST): a multicentre, open-label, randomised controlled trial.
Roaldsen MB; Eltoft A; Wilsgaard T; Christensen H; Engelter ST; Indredavik B; Jatužis D; Karelis G; Kõrv J; Lundström E; Petersson J; Putaala J; Søyland MH; Tveiten A; Bivard A; Johnsen SH; Mazya MV; Werring DJ; Wu TY; De Marchis GM; Robinson TG; Mathiesen EB;
Lancet Neurol; 2023 Feb; 22(2):117-126. PubMed ID: 36549308
[TBL] [Abstract][Full Text] [Related]
3. Statistical analysis plan for the randomized controlled trial Tenecteplase in Wake-up Ischaemic Stroke Trial (TWIST).
Eltoft A; Wilsgaard T; Roaldsen MB; Søyland MH; Lundström E; Petersson J; Indredavik B; Putaala J; Christensen H; Kõrv J; Jatužis D; Engelter ST; De Marchis GM; Werring DJ; Robinson T; Tveiten A; Mathiesen EB
Trials; 2022 May; 23(1):421. PubMed ID: 35590386
[TBL] [Abstract][Full Text] [Related]
4. Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol.
Bivard A; Garcia-Esperon C; Churilov L; Spratt N; Russell M; Campbell BC; Choi P; Kleinig T; Ma H; Markus H; Molina C; Hsu C; Tsai CH; Meretoja A; Strbian D; Butcher K; Wu T; Davis S; Donnan G; Levi C; Parsons M
Int J Stroke; 2023 Jul; 18(6):751-756. PubMed ID: 36655938
[TBL] [Abstract][Full Text] [Related]
5. Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
Kvistad CE; Næss H; Helleberg BH; Idicula T; Hagberg G; Nordby LM; Jenssen KN; Tobro H; Rörholt DM; Kaur K; Eltoft A; Evensen K; Haasz J; Singaravel G; Fromm A; Thomassen L
Lancet Neurol; 2022 Jun; 21(6):511-519. PubMed ID: 35525250
[TBL] [Abstract][Full Text] [Related]
6. A Phase III, prospective, double-blind, randomized, placebo-controlled trial of thrombolysis in imaging-eligible, late-window patients to assess the efficacy and safety of tenecteplase (TIMELESS): Rationale and design.
Albers GW; Campbell BC; Lansberg MG; Broderick J; Butcher K; Froehler MT; Schwamm LH; Nouh AM; Liebeskind DS; Toy F; Yang M; Massaro L; Schoeffler M; Purdon B
Int J Stroke; 2023 Feb; 18(2):237-241. PubMed ID: 35262424
[TBL] [Abstract][Full Text] [Related]
7. Tenecteplase versus alteplase in acute ischaemic cerebrovascular events (TRACE-2): a phase 3, multicentre, open-label, randomised controlled, non-inferiority trial.
Wang Y; Li S; Pan Y; Li H; Parsons MW; Campbell BCV; Schwamm LH; Fisher M; Che F; Dai H; Li D; Li R; Wang J; Wang Y; Zhao X; Li Z; Zheng H; Xiong Y; Meng X;
Lancet; 2023 Feb; 401(10377):645-654. PubMed ID: 36774935
[TBL] [Abstract][Full Text] [Related]
8. Tenecteplase versus standard of care for minor ischaemic stroke with proven occlusion (TEMPO-2): a randomised, open label, phase 3 superiority trial.
Coutts SB; Ankolekar S; Appireddy R; Arenillas JF; Assis Z; Bailey P; Barber PA; Bazan R; Buck BH; Butcher KS; Camden MC; Campbell BCV; Casaubon LK; Catanese L; Chatterjee K; Choi PMC; Clarke B; Dowlatshahi D; Ferrari J; Field TS; Ganesh A; Ghia D; Goyal M; Greisenegger S; Halse O; Horn M; Hunter G; Imoukhuede O; Kelly PJ; Kennedy J; Kenney C; Kleinig TJ; Krishnan K; Lima F; Mandzia JL; Marko M; Martins SO; Medvedev G; Menon BK; Mishra SM; Molina C; Moussaddy A; Muir KW; Parsons MW; Penn AMW; Pille A; Pontes-Neto OM; Roffe C; Serena J; Simister R; Singh N; Spratt N; Strbian D; Tham CH; Wiggam MI; Williams DJ; Willmot MR; Wu T; Yu AYX; Zachariah G; Zafar A; Zerna C; Hill MD;
Lancet; 2024 Jun; 403(10444):2597-2605. PubMed ID: 38768626
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes and safety profile of Tenecteplase in wake-up stroke.
Ahmed HK; Logallo N; Thomassen L; Novotny V; Mathisen SM; Kurz MW
Acta Neurol Scand; 2020 Nov; 142(5):475-479. PubMed ID: 32511749
[TBL] [Abstract][Full Text] [Related]
10. Tenecteplase versus Alteplase for Stroke Thrombolysis Evaluation Trial in the Ambulance (Mobile Stroke Unit-TASTE-A): protocol for a prospective randomised, open-label, blinded endpoint, phase II superiority trial of tenecteplase versus alteplase for ischaemic stroke patients presenting within 4.5 hours of symptom onset to the mobile stroke unit.
Bivard A; Zhao H; Coote S; Campbell B; Churilov L; Yassi N; Yan B; Valente M; Sharobeam A; Balabanski A; Dos Santos A; Ng F; Langenberg F; Stephenson M; Smith K; Bernard S; Thijs V; Cloud G; Choi P; Ma H; Wijeratne T; Chen C; Olenko L; Davis SM; Donnan GA; Parsons M
BMJ Open; 2022 Apr; 12(4):e056573. PubMed ID: 35487712
[TBL] [Abstract][Full Text] [Related]
11. Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
Menon BK; Buck BH; Singh N; Deschaintre Y; Almekhlafi MA; Coutts SB; Thirunavukkarasu S; Khosravani H; Appireddy R; Moreau F; Gubitz G; Tkach A; Catanese L; Dowlatshahi D; Medvedev G; Mandzia J; Pikula A; Shankar J; Williams H; Field TS; Manosalva A; Siddiqui M; Zafar A; Imoukhuede O; Hunter G; Demchuk AM; Mishra S; Gioia LC; Jalini S; Cayer C; Phillips S; Elamin E; Shoamanesh A; Subramaniam S; Kate M; Jacquin G; Camden MC; Benali F; Alhabli I; Bala F; Horn M; Stotts G; Hill MD; Gladstone DJ; Poppe A; Sehgal A; Zhang Q; Lethebe BC; Doram C; Ademola A; Shamy M; Kenney C; Sajobi TT; Swartz RH;
Lancet; 2022 Jul; 400(10347):161-169. PubMed ID: 35779553
[TBL] [Abstract][Full Text] [Related]
12. Tenecteplase Thrombolysis for Acute Ischemic Stroke.
Warach SJ; Dula AN; Milling TJ
Stroke; 2020 Nov; 51(11):3440-3451. PubMed ID: 33045929
[TBL] [Abstract][Full Text] [Related]
13. Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke (EXTEND-IA TNK Part 2): A multicenter, randomized, controlled study.
Campbell BC; Mitchell PJ; Churilov L; Yassi N; Kleinig TJ; Yan B; Thijs V; Desmond PM; Parsons MW; Donnan GA; Davis SM
Int J Stroke; 2020 Jul; 15(5):567-572. PubMed ID: 31564231
[TBL] [Abstract][Full Text] [Related]
14. The Norwegian tenecteplase stroke trial (NOR-TEST): randomised controlled trial of tenecteplase vs. alteplase in acute ischaemic stroke.
Logallo N; Kvistad CE; Nacu A; Naess H; Waje-Andreassen U; Asmuss J; Aamodt AH; Lund C; Kurz MW; Rønning OM; Salvesen R; Idicula TT; Thomassen L
BMC Neurol; 2014 May; 14():106. PubMed ID: 24886064
[TBL] [Abstract][Full Text] [Related]
15. Tenecteplase, 0.4 mg/kg, in Moderate and Severe Acute Ischemic Stroke: A Pooled Analysis of NOR-TEST and NOR-TEST 2A.
Novotny V; Kvistad CE; Naess H; Logallo N; Fromm A; Khanevski AN; Thomassen L
J Am Heart Assoc; 2023 Oct; 12(20):e030320. PubMed ID: 37830342
[TBL] [Abstract][Full Text] [Related]
16. Tenecteplase for Stroke at 4.5 to 24 Hours with Perfusion-Imaging Selection.
Albers GW; Jumaa M; Purdon B; Zaidi SF; Streib C; Shuaib A; Sangha N; Kim M; Froehler MT; Schwartz NE; Clark WM; Kircher CE; Yang M; Massaro L; Lu XY; Rippon GA; Broderick JP; Butcher K; Lansberg MG; Liebeskind DS; Nouh A; Schwamm LH; Campbell BCV;
N Engl J Med; 2024 Feb; 390(8):701-711. PubMed ID: 38329148
[TBL] [Abstract][Full Text] [Related]
17. Evolving Thrombolytics: from Alteplase to Tenecteplase.
Miller SE; Warach SJ
Neurotherapeutics; 2023 Apr; 20(3):664-678. PubMed ID: 37273127
[TBL] [Abstract][Full Text] [Related]
18. Tenecteplase for the treatment of acute ischemic stroke: A review of completed and ongoing randomized controlled trials.
Coutts SB; Berge E; Campbell BC; Muir KW; Parsons MW
Int J Stroke; 2018 Dec; 13(9):885-892. PubMed ID: 30035698
[TBL] [Abstract][Full Text] [Related]
19. Routine Use of Tenecteplase for Thrombolysis in Acute Ischemic Stroke.
Zhong CS; Beharry J; Salazar D; Smith K; Withington S; Campbell BCV; Wilson D; Le Heron C; Mason D; Duncan R; Reimers J; Mein-Smith F; Diprose WK; Barber PA; Ranta A; Fink JN; Wu TY
Stroke; 2021 Mar; 52(3):1087-1090. PubMed ID: 33588597
[TBL] [Abstract][Full Text] [Related]
20. Intravenous Thrombolysis With Tenecteplase in Patients With Large Vessel Occlusions: Systematic Review and Meta-Analysis.
Katsanos AH; Safouris A; Sarraj A; Magoufis G; Leker RR; Khatri P; Cordonnier C; Leys D; Shoamanesh A; Ahmed N; Alexandrov AV; Tsivgoulis G
Stroke; 2021 Jan; 52(1):308-312. PubMed ID: 33272127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
